This small randomised phase 2 trial found longer progression-free survival with ablation in selected lung cancer after an immunotherapy response. It did not test SBRT or establish one ablation method as universally best.
Single-centre open-label trial in advanced non-small-cell lung cancer with limited residual disease after first-line anti-PD-1/PD-L1 treatment and no progression before randomisation. Sixty-five patients were allocated 2:1; the main analysis included 42 with ablation plus continuing immunotherapy and 20 with immunotherapy alone after three withdrawals. Eligible lung residual lesions were ablated; this was not treatment of every disease site.
The primary progression-free survival clock began at immunotherapy initiation, before randomisation. The main text also reports a separate analysis starting at randomisation. Keep those clocks and denominators separate when comparing estimates with another trial. The study enrolled fewer patients than planned and needs confirmation.
Provides a hypothesis-supporting result for this selected residual-lung-disease setting. It does not establish the same effect for breast cancer, oligoprogression, every local method or a proposed immune mechanism.
Shares Systemic versus local therapy, Non-small-cell lung cancer and the tags education-audit, local-treatment.
Shares Systemic versus local therapy and the tags education-audit, local-treatment.
Shares Systemic versus local therapy and the tags education-audit, local-treatment.
Shares Non-small-cell lung cancer and the tags education-audit, local-treatment.
Shares the tags education-audit, local-treatment.
Shares the tags education-audit, local-treatment.
Shares the tags education-audit, local-treatment.
Shares the tags education-audit, local-treatment.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/